This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove Development Remove Genotoxicity Remove In-Vitro Remove In-Vivo
article thumbnail

The Future for Biotesting

Pharmaceutical Technology

SEPTEMBER 10, 2008

The first activities of the company concerned the pre-clinical toxicological testing of several new candidate molecules showing cytostatic activity, initially developed by a former research institute, as well as the breeding and supplying of laboratory animals. . Dr Ivana Surovà: Biotest s.r.o. Can you reveal the results of these?

In-Vitro 130
In-Vitro Genotoxicity In-Vivo Clinical Research 130
article thumbnail

Accelerating NDA filing through faster carcinogenicity assessment

Drug Discovery World

MAY 10, 2023

Drug discovery and development is an arduous process that can cost upwards of $2.6 Until recently, drug carcinogenicity assessment required two different in vivo studies, one of which was typically a two-year lifetime study in rats. billion and take over 10 years.

Bioassay 52
Bioassay Genotoxicity Drugs In-Vivo 52
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 32,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024